Correction to: BMC Nephrology 22, 391 (2021)
https://doi.org/10.1186/s12882-021-02601-w
Following publication of the original article [1], the authors would like to correct a spelling mistake in title and in the body of the text.
The word currently reads: Alpha
The word should read: Alfa
The title has been updated above and the original article [1] has been corrected.
Reference
Lim et al. A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure. BMC Nephrol. 2021;22:391. https://doi.org/10.1186/s12882-021-02601-w.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lim, S.K., Goh, B.L., Visvanathan, R. et al. Correction to: A multicentre, multi-national, double-blind, randomised, active-controlled, parallel-group clinical study to assess the safety and efficacy of PDA10 (Epoetin-Alfa) vs. Eprex® in patients with anaemia of chronic renal failure. BMC Nephrol 23, 14 (2022). https://doi.org/10.1186/s12882-021-02651-0
Published:
DOI: https://doi.org/10.1186/s12882-021-02651-0